pociredir   Click here for help

GtoPdb Ligand ID: 11523

Synonyms: Example 90 [WO2020190754] | FTX-6058 | FTX6058
Compound class: Synthetic organic
Comment: FTX-6058 binds to embryonic ectoderm development (EED) and induces foetal haemoglobin (HbF) tetramer production via modulation of PRC2. It was developed by Fulcrum Therapeutics as an oral drug for the treatment of sickle cell disease or beta thalassemia. We matched the chemical structure for the INN 'pociredir' (from the WHO's proposed INN list 127, July 2022) to the structure for FTX-6058.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 73.57
Molecular weight 403.14
XLogP 5.74
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cc1ncccc1c1cc2OC[C@H]3COc4c3c(CNc2n2c1nnc2)c(F)cc4
Isomeric SMILES Cc1ncccc1c1cc2OC[C@H]3COc4c3c(CNc2n2c1nnc2)c(F)cc4
InChI InChI=1S/C22H18FN5O2/c1-12-14(3-2-6-24-12)15-7-19-22(28-11-26-27-21(15)28)25-8-16-17(23)4-5-18-20(16)13(9-29-18)10-30-19/h2-7,11,13,25H,8-10H2,1H3/t13-/m1/s1
InChI Key JQBUTSBIFNKJMW-CYBMUJFWSA-N
No information available.
Summary of Clinical Use Click here for help
Pociredir (FTX-6058) has been advanced to early stage clinical evaluations, to determine safety, tolerability and PK/PD of orally administered pociredir.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04586985 Safety, Tolerability and Pharmacokinetics of FTX-6058 Phase 1 Interventional Fulcrum Therapeutics
NCT05169580 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 Phase 1 Interventional Fulcrum Therapeutics